Global Non-Small Cell Lung Cancer Pipeline Assessments 2019: Therapeutic Analysis by Developmental Stage, Associated Indications, Route of Administration and Molecule Type


DUBLIN, March 11, 2019 –The “Non-Small Cell Lung Cancer – Pipeline Insight, 2019” drug pipelines has been added to’s offering.

The report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Non-Small Cell Lung Cancer development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:

  • Clinical
  • Non-clinical
  • Inactive: Discontinued and/or Dormant

Descriptive coverage of pipeline development activities for Non-Small Cell Lung Cancer

Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Pipeline Therapeutics assessment of products for Non-Small Cell Lung Cancer

The report assesses the active Non-Small Cell Lung Cancer pipeline products by developmental stage, product type, molecule type, and administration route.

Scope of the report

  • The report provides a snapshot of the pipeline development for the Non-Small Cell Lung Cancer
  • The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for the Non-Small Cell Lung Cancer
  • The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
  • Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Non-Small Cell Lung Cancer
  • The report also covers the dormant and discontinued pipeline projects related to the Non-Small Cell Lung Cancer

Reasons to Buy

  • Establish comprehensive understanding of the pipeline activity across this Non-Small Cell Lung Cancer to formulate effective R&D strategies
  • Gather information of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
  • Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine
  • Plot corrective measures for pipeline projects by understanding the pipeline depth and focus of Non-Small Cell Lung Cancer therapeutics
  • Devise in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying inactive projects and understanding the factors that might have halted their progress

Key Topics Covered:

1. Report Introduction

2. Non-Small Cell Lung Cancer Overview

3. Pipeline Therapeutics

  • An Overview of Pipeline Products for Non-Small Cell Lung Cancer

4. Comparative Analysis

5. Products in Clinical Stage

  • Product Description
  • Research and Development
  • Product Development Activities

6. Products in Pre-Clinical and Discovery Stage

  • Product Description
  • Research and Development
  • Product Development Activities

7. Therapeutic Assessment

  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

8. Inactive Products

  • Product Description
  • Research and Development
  • Product Development Activities


Companies Mentioned

  • Eli Lilly
  • Allergan
  • Amgen
  • Acerta Pharma
  • Genentech
  • Pfizer
  • AstraZeneca
  • Peregrine Pharmaceuticals
  • Spectrum Pharmaceuticals
  • BIND Therapeutics

For more information about this drug pipelines report visit

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager

For E.S.T Office Hours Call +1-917-300-0470

For U.S./CAN Toll Free Call +1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907

Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

Related Links